Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World

Diagnostic-Therapeutic Pathway and Outcomes of Early Stage NSCLC: a Focus on EGFR Testing in the Real-World

BackgroundOsimertinib is considered the standard-of-care for previously-untreated EGFR mutant advanced non-small cell lung cancer (NSCLC). Oncogene driver screening in early NSCLC is not standard practice. A real-world study has been designed in order to investigate the optimal testing frequency and...

Full description

Bibliographic Details
Main Authors: Giulia Pasello, Martina Lorenzi, Giulia Pretelli, Giovanni Maria Comacchio, Federica Pezzuto, Marco Schiavon, Alessandra Buja, Stefano Frega, Laura Bonanno, Valentina Guarneri, Fiorella Calabrese, Federico Rea
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Oncology
Subjects:
NSCLC
early-stage
real-world
EGFR
costs
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.909064/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.909064/full

Similar Items